Yadanzigan

Yadanzigan (YDZG) is an anti-inflammatory agent and a NLRP3 inhibitor. Yadanzigan specifically inhibits NLRP3 activation via inhibiting NF-κB pathway and Reactive Oxygen Species production. Yadanzigan also moderates LPS -induced acute lung injury (ALI) in mice[1].

76588-87-9

YDZG

12352005

NF-κB; NOD-like Receptor (NLR) ; Reactive Oxygen Species (ROS)

Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB

Inflammation/Immunology

10 mM in DMSO

CC1=C[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@@]3(C)[C@H]1C[C@@H]4[C@]56[C@@H]3[C@@H](O)[C@H](O)[C@@](OC6)(C)[C@]5(O)[C@@H](O)C(O4)=O

C26H38O14

574.57

[1]Cui Y, et al. Yadanzigan, a quassinoid glucoside, attenuates NLRP3 inflammasome activation to prevent LPS-induced acute lung injury. Authorea Preprints, 2020.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-N10312/

Natural Products

No Development Reported

NLRP3